CR20220062A - Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina - Google Patents
Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazinaInfo
- Publication number
- CR20220062A CR20220062A CR20220062A CR20220062A CR20220062A CR 20220062 A CR20220062 A CR 20220062A CR 20220062 A CR20220062 A CR 20220062A CR 20220062 A CR20220062 A CR 20220062A CR 20220062 A CR20220062 A CR 20220062A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pyrazolo
- pyrazine
- phosphatase inhibitors
- shp2 phosphatase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invencion proporciona nuevos derivados de pirazina de formula (I): (I) <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAVcAAAE+CAYAAAA5ylOKAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAACbDSURBVHhe7d1/aJXn/f/xy+9/tcXhrN2Q+bO0apdZ7RoRVHSuOC0DZS5/tIi6Gd2oP9gYcaJuKqjY+sdA126oZU0pWtAM/adRcUUxUuecqZto0+HPFBmzaUdZMxiDfH1eva/zuXN2cnKSc/+47vu8HhCSc4zmTuJ53df9vq/3dQ3pecCIiEik/l/wXkREIqRwFRGJgcJVRCQGClcRkRgoXEVEYqBwFRGJgcJVRCQGClcRkRgoXEVEYqBwFRGJgcJVRCQGClcRkRgoXEVEYqBwFRGJgcJVRCQGClcRkRgoXEVEYqBwFRGJgcJVRCQGClcRkRhog0IRidVHH31kuru7g0fGPPnkk8FH+aaRq4jE6s6dO+bq1avm6NGjZunSpcGz+aeRq4gkYvHixeaVV17RyFVEpFIbNmwwQ4YM6fX261//OvhTY86fP29DtVaCFQpXEYlES0uL4UKYt/b2drNu3TrzySef2D87e/asefHFF+3HtULhKiKxu3jxopk4cWLwqDYoXEUkEkuWLCmUBLZt22ZOnjxpvvzlL9s/o9b60EMP2Y9rhcJVRCJBWaCrq8vs27fP3Lt3zzz11FPBn9TO9KswhauIRIaR6tq1a83cuXPN9u3bg2drk8JVRCK3ceNGc/DgQfP73/8+eKb2aJ6riFSNLqyhQ4cWaqzgOXzta1+z72uNwlVEJAYqC4hIJHbt2hV8JFC4ikjVKAEcO3YseCRQuIqkgM4leu15ozU0665du2aWLVsWPBIoXEVScOjQIfPSSy+Zw4cPm1mzZgXPZtelS5fMtGnTgkcC3dASicmbb75pl9oLW7RokZk5c6Y5deqUDaTnn3/ehlLWX4bTp083J06c6DVboNZp5CoSE4J1zJgxprGx0b7V1dXZUSr1ydmzZ9spSm1tbaa+vj74G9n04YcfmlGjRilYiyhcRWJE6Lil9hoaGuxzrMp/7tw5+zHPP/300/bjrOIk8r3vfS94JI7KAiIxYY1TRnWur56PR44caQ4cOGD+/e9/24D9+9//bkM3y4uarFq1yqxZs8ZMnTo1eEagcBWJCeGKGTNmmNbWVnP//n17AytPq0NxkqAzi9F4ra161R+VBURiRLByybx37177eOvWrfZ9XnR0dNh6soL1fylcRRJA+LCm6Z49e3Ixr9X5y1/+YhYuXBg8kjCFq0hMmHbFDAGH2iuzAz7//PPgmexj1avw9yj/RzVXkZQw13X+/PnBo+yhy2zEiBGZn6MbF41cRVJy5MiRXjukZs3169fNzp07g0dSTOEqkpKXX37ZdnFltQbLDq/PPvts8EiKKVxFUkJHEzXLn/70p5kMWE4M4X2ypDeFq0iKaIElYGmLpckgK2jhpfusVncZqITCVSRlbo2BpUuXFrZG8R1LDD733HPBIylF4SriAVbK+tWvfmUbDrIQsFpisH+aiiXiEeqYrDlAR5fPXU9DhgwxXV1dWgmrDI1cRTzCav6skrV+/Xrbt+8jasO0vCpYy1O4inhm7dq1Zvz48TZgfXThwgW7Hq2Up3AV8RDTs+BjkwFliylTpgSPpC+quYp4irIAo1fKBIxm08bx/O1vf7PHoyUG+6eRq4inCC/XxcU6BEmjtsrXZfTMLrWs2/rGG2+Y0aNHm8uXLwefJX3RyFXEc0zNYooWU7WYshUHvsadO3fMjRs37LYtLI3Iql7MZWU1r3HjxhV2VEjiePJA4SqSAQQaI0b6+avdToXLexa5vnnzpr05debMGfs8o9NJkybZJQT5WuUu+93x8O+40JXeFK4iGcH6A9zool12IG2nXN7fvn3bTvy/ePGiOX78uGlqarIhyo0pdqitZFoVocyb+9zBHk+tULiKZEh/geYu7xnhXrlyxRw8eNDOSeUmFCNMFloZbBC+//77ZvXq1b2+tgK2bwpXkYzhBhdh9tprr5l//OMfhct7VyedPn164fI+6kt297XDGy1mpassaQpXkQxiBMkW3VzeswnihAkTKr68rxazBxgVh8O01HO1TuEqkkGrVq0yK1asSO1u/a5du8ytW7dswDs8989//tNuxCgKV5HM4aYSc07TnMjPMRQ3OJR6rpapiUAkY5jAz95VLli5qcTNpiTxtSkBUApwLbqlnssaNl2kcYKfabUUriIZc/bsWTNnzpzgkbE3stJAmBZ3kIWfiyKgksTIe8GCBeaxxx6znWjV7gyhsoBIhhSXBBhpEQjMX01LqY4tX7u4+Pl1dnYGj77Az5NpZITphg0b7GwLNl6sdttzjVxFMqS4JEBjAGvApolgYnoW+4C58kT4uWpHgFEiWCdOnGjn//JGmNJp5o773r175vnnn7fbnldbalG4imRIcUmAECDA0kaYsg8YU8QYtYaf83FvMGY08Hbs2DGzb98+884779iQ5WYc7cWsV8sc4mooXEUygkvazZs3m8mTJ9vHlAS4eVTtWgNR4fK/eB+wUs/5gNG0e+NnSNMFVwMLFy6009y4IUdpoBqquYpkBDeIuNHi5pZyE4lw8G3aE+UAbmj52MXFz4uyQFhzc7NpaGiI/Lg0chXJCEoChIDjS0mgGKNUlioM7wOWxt5g1EwJdTcSDWNMyU1B1l0g9OMIfI1cRTLAzRJwO65SEhgxYoTXOwK4ltikurgoO1y7ds2cPn3aTk8jOKmdsvKXK524kauLPf4OtdaWlhZ7UoiSwlUkA0qVBJgpsGnTJvvYR5wQ4uzi4gRz/fp1O6LnxtSoUaPsiHnatGnmmWeeKXnSKQ5XUMZYsmRJ5FuFK1xFMoBRICtcubmXaa8tUKkoA5a/x+LczEBgdMq0KRb45sYTb0ksWjMQCleRDGBi+4kTJzJTEggjFJk+tmPHjsLJwTU/9NdkwEiTbWdaW1vtvFS3ClgcyylGjnAVEX+1t7f3NDY2Bo96eh6M3Hp27twZPMqGzs7Onvr6envsTl/PnTx50n5/xBPfd3Nzs/0ZPDiZBJ+VDRq5iniuuCTATSFGgr6XBIpx84ibRvv37y/cYHI3lH7yk58U1iJgZgF1U+bz+napPxAKVxHPhUsCXGKnvdxgNQhQtoVx3w9+8IMfmLFjx9q7+3R15YXCVcRjzNV89dVXC7MECCfujvs8S6A/jFapGXNyyPrJohw1EYh4jDvjzNV0itcWyCJGpy5IWYiGm1R5C1Zo5CriMUoCzMMkkPI4yqN+HMXyfj7SyFXEU5QEmBjv6pCM8qhL5iVYOVmwEE21C6T4SuEq4ilKAuGWzOK1BbLOnSyyPCOgHIWriKfoQpo3b579OI+jvLydLIopXEU8xB11FJcE8jTKYz2AvJYEoHAV8dC7777bqyTQ3t6eq1Ee9WTWFshrSQAKVxEPMUPAlQTAuqR5GuVRT85zSQAKVxHPFJcE8jjKy9vJohSFq4hniksCeRvl1UJJAApXEc+wtF54nye2cgl3aWUdJws2Asw7hauIZxi1ErBMvwIrSOWpPZSSAJ1neadwFfEMy+9x2cxq/XlT3HWWZwpXEQ+tXLnSvi/etTTrirvO8kzhKuIhygDs8c/uqXkKWEoC4SlmeaZwFfGUC1gCid1es44pZrVSEoDCVcRjBCwNBVu2bClsg5JVxVPM8k7hKuI5RnoELNujcEMoq4q7zvJO4SqSAQQs21CvXr260MGVJcVdZ7VA4SqSEez2SsByaZ21gK21kgAUrtIvJrN/8sknwSNJEwG7ceNGs3bt2kKTQRZQEpgyZUrwqDYoXKUsXsBMZj9 (***)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1911928.8A GB201911928D0 (en) | 2019-08-20 | 2019-08-20 | Pharmaceutical compounds |
PCT/IB2020/057815 WO2021033153A1 (en) | 2019-08-20 | 2020-08-20 | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220062A true CR20220062A (es) | 2022-04-20 |
Family
ID=68099585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220062A CR20220062A (es) | 2019-08-20 | 2020-08-20 | Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230049719A1 (es) |
EP (1) | EP4017855A1 (es) |
JP (1) | JP2022546213A (es) |
KR (1) | KR20220049518A (es) |
CN (1) | CN114206885A (es) |
AU (1) | AU2020333251A1 (es) |
BR (1) | BR112022003184A2 (es) |
CA (1) | CA3148312A1 (es) |
CL (1) | CL2022000271A1 (es) |
CO (1) | CO2022001357A2 (es) |
CR (1) | CR20220062A (es) |
EC (1) | ECSP22011086A (es) |
GB (1) | GB201911928D0 (es) |
IL (1) | IL289462A (es) |
MX (1) | MX2022001908A (es) |
PE (1) | PE20220931A1 (es) |
TW (1) | TW202124383A (es) |
WO (1) | WO2021033153A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111902415A (zh) | 2018-03-02 | 2020-11-06 | 大冢制药株式会社 | 药学化合物 |
MX2021000795A (es) | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
WO2022014640A1 (ja) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ |
KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ras阻害剤としてのインドール誘導体 |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
EP4334321A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors |
TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
CN116323616A (zh) * | 2021-07-07 | 2023-06-23 | 浙江同源康医药股份有限公司 | 用作shp2抑制剂的化合物及其应用 |
EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
CN118019743A (zh) * | 2021-09-28 | 2024-05-10 | 甘李药业股份有限公司 | 可用作shp2抑制剂的化合物及其制备方法和用途 |
WO2023051717A1 (zh) * | 2021-09-29 | 2023-04-06 | 微境生物医药科技(上海)有限公司 | 作为shp2抑制剂的稠环化合物 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
JP7044375B2 (ja) * | 2016-05-31 | 2022-03-30 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Ptpn11の複素環式阻害剤 |
CN112250670B (zh) * | 2016-06-07 | 2021-06-08 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
US11529347B2 (en) * | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
EP3768680A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
EP3787627A4 (en) | 2018-05-02 | 2021-12-01 | Navire Pharma, Inc. | SUBSTITUTED HETEROCYCLIC INHIBITORS FOR PTPN11 |
-
2019
- 2019-08-20 GB GBGB1911928.8A patent/GB201911928D0/en not_active Ceased
-
2020
- 2020-08-20 CN CN202080056769.9A patent/CN114206885A/zh active Pending
- 2020-08-20 AU AU2020333251A patent/AU2020333251A1/en active Pending
- 2020-08-20 JP JP2022506960A patent/JP2022546213A/ja active Pending
- 2020-08-20 US US17/753,048 patent/US20230049719A1/en active Pending
- 2020-08-20 EP EP20761906.5A patent/EP4017855A1/en active Pending
- 2020-08-20 CR CR20220062A patent/CR20220062A/es unknown
- 2020-08-20 TW TW109128416A patent/TW202124383A/zh unknown
- 2020-08-20 KR KR1020227004594A patent/KR20220049518A/ko unknown
- 2020-08-20 WO PCT/IB2020/057815 patent/WO2021033153A1/en active Application Filing
- 2020-08-20 CA CA3148312A patent/CA3148312A1/en active Pending
- 2020-08-20 PE PE2022000239A patent/PE20220931A1/es unknown
- 2020-08-20 MX MX2022001908A patent/MX2022001908A/es unknown
- 2020-08-20 BR BR112022003184A patent/BR112022003184A2/pt unknown
-
2021
- 2021-12-28 IL IL289462A patent/IL289462A/en unknown
-
2022
- 2022-02-02 CL CL2022000271A patent/CL2022000271A1/es unknown
- 2022-02-10 CO CONC2022/0001357A patent/CO2022001357A2/es unknown
- 2022-02-11 EC ECSENADI202211086A patent/ECSP22011086A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP22011086A (es) | 2022-03-31 |
CA3148312A1 (en) | 2021-02-25 |
IL289462A (en) | 2022-02-01 |
WO2021033153A1 (en) | 2021-02-25 |
US20230049719A1 (en) | 2023-02-16 |
CL2022000271A1 (es) | 2022-10-28 |
MX2022001908A (es) | 2022-04-18 |
CO2022001357A2 (es) | 2022-03-18 |
GB201911928D0 (en) | 2019-10-02 |
AU2020333251A1 (en) | 2022-02-17 |
CN114206885A (zh) | 2022-03-18 |
BR112022003184A2 (pt) | 2022-05-17 |
EP4017855A1 (en) | 2022-06-29 |
JP2022546213A (ja) | 2022-11-04 |
KR20220049518A (ko) | 2022-04-21 |
PE20220931A1 (es) | 2022-05-31 |
TW202124383A (zh) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001908A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina. | |
NZ766835A (en) | Pharmaceutical compounds | |
PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
MX2021006026A (es) | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. | |
GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
MX2022003102A (es) | Degradadores bifuncionales de brd9 y sus metodos de uso. | |
MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
MX2020013785A (es) | Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. | |
MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
MX2021007247A (es) | Derivados de rapamicina. | |
MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
MX2018010177A (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida. | |
MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
PH12020500436A1 (en) | Aromatic derivative, preparation method for same, and medical applications thereof |